U.S., May 13 -- ClinicalTrials.gov registry received information related to the study (NCT07582120) titled 'Psilocybin-Assisted Therapy as a Treatment for Depression' on May 05.
Brief Summary: Depression is the leading cause of disability worldwide, affecting an estimated 300 million people. Despite available treatments, response rates remain modest, and treatment resistance is common. Novel treatments are needed that act rapidly, produce lasting effects and work differently than existing antidepressants.
In clinical trials, psilocybin has shown promise as a treatment for depression due to its rapid onset of antidepressant effects and sustained benefits.
This study will use MRI scanning of the brain and other biological measures (biomark...